Combining vibration treatment and HMB supplementation to improve muscle health in older adults
Dissecting the Therapeutic Mechanism of an Effective Combination Treatment Targeting Neuromuscular Junction Dengeneration and Myosteatosis to Combat Sarcopenia
This study is testing whether combining vibration treatment with a supplement called HMB can help older adults with muscle loss get stronger and improve their overall muscle health.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 60 Years and up |
| Sex | All |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 3 sites (Hong Kong and 2 other locations) |
| Trial ID | NCT05525039 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the combined effects of low-magnitude high-frequency vibration treatment and β-hydroxy β-methylbutyrate (HMB) supplementation on muscle strength and mass in older adults diagnosed with sarcopenia. Participants aged 60 and above will be screened and randomized into four groups: control, HMB only, vibration treatment only, and a combination of both for a duration of six months. The study aims to assess changes in hand grip strength, gait speed, and muscle mass using bioelectric impedance analysis. The primary outcome is to evaluate improvements in muscle strength, which is crucial for functional ability in this population.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 60 and above who have been identified as having sarcopenia based on specific screening criteria.
Not a fit: Patients with pathological bone diseases, chronic inflammatory conditions, or those who are chair- or bed-bound may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly enhance muscle strength and overall physical function in older adults suffering from sarcopenia.
How similar studies have performed: Previous studies have shown promising results with similar interventions, indicating potential for clinical success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects aged 60 years or above * Subjects failed in AWGS algorithm 1. skeletal muscle mass by BIA (male at \<7.0 kg/m\^2, female at \<5.7 kg/m\^2), and 2. handgrip strength (male at \<28 kg, female at \<18kg), and/or 3. gait speed test (\>1m/s) Exclusion Criteria: * Subjects with pathological bone diseases * Subjects with chronic inflammatory condition (e.g. rheumatoid arthritis) * Subjects with neurological problems * Subjects receiving regular exercise * Subjecs who are chair-/bed- bound * Subjects with malignancy * Subjects with cardiovascular concern such as with pace-maker in-situ * Subjects with acute fractures or severe osteoarthritis
Where this trial is running
Hong Kong and 2 other locations
- Evangelical Luthera Church Social Service - Hong Kong — Hong Kong, Hong Kong (Active_not_recruiting)
- The Chinese University of Hong Kong Jockey Club Centre for Osteoporosis Care and Control — Hong Kong, Hong Kong (Recruiting)
- The Chinese University of Hong Kong, Department of Orthopaedics and Traumatology, 1/F Li Ka Shing Outpatient Clinic (North), PWH — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Wing Hoi Cheung, PhD — Chinese University of Hong Kong
- Study coordinator: Wing Hoi Cheung, PhD
- Email: louischeung@cuhk.edu.hk
- Phone: 35052715
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.